Is Lexeo Therapeutics (LXEO) One of Billionaire Daniel Sundheim’s Stock Picks with Huge Upside Potential

Lexeo Therapeutics (NASDAQ:LXEO) is one of billionaire Daniel Sundheim’s stock picks with huge upside potential. On October 21, Leerink’s Mani Foroohar lowered the price target on Lexeo Therapeutics (NASDAQ:LXEO) from $20 to $18 but maintained an Outperform rating.

Likoper/Shutterstock.com The revision followed Lexeo’s $135 million capital raise through a secondary offering and private placement, along with new data from its LX2020 PKP2 program. Leerink viewed the move as a smart step to strengthen the company’s financial position ahead of its upcoming FACM trial, keeping the spotlight on clinical progress rather than funding concerns. Earlier, on October 16, Lexeo Therapeutics announced a public offering and private placement totaling roughly $135 million in gross proceeds. The company offered over 15.6 million shares at $8 each, with underwriters granted a 30-day option to buy more. Lexeo Therapeutics (NASDAQ:LXEO) is a clinical-stage genetic medicine company focused on developing adeno-associated virus (AAV)-based gene therapies for genetically defined cardiovascular diseases and a specific form of Alzheimer’s disease. The company uses cutting-edge science to create treatments that address the underlying genetic causes of these devastating conditions. While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.